Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Short-Term Drug Therapy for Beta-Cell Function in T2DM
NCT04027023Phase 4Unknown
- Sponsor
- Sciema
- Start
- Oct 2019
- Primary completion
- Apr 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of insulin glargine, insulin degludec, liraglutide, exenatide, pioglitazone in type 2 diabetes mellitus (T2DM), sponsored by Sciema. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04027023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027023.